Partner News | Published: Friday, October 9, 2026
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, is excited to announce an industry partnership with AISAP, a health-technology company bringing AI-powered cardiac diagnostics to the point of care. AISAP’s flagship platform, AISAP Cardio, is a U.S. Food and Drug Administration (FDA)-cleared AI solution that gives cardiovascular programs a scalable way to turn bedside cardiac ultrasound scans into comprehensive cardiac assessment reports, expanding access to care in rural health and other underserved settings while driving real impact through greater diagnostic efficiency and stronger patient care management.
AISAP Cardio is a comprehensive AI solution for diagnosing heart failure and structural heart disease using ultrasound. The platform integrates with ultrasound devices across manufacturers, and every report connects automatically into any electronic health record (EHR) system. By analyzing 12 key cardiac measurements and findings, from ejection fraction to valvular pathology, AISAP Cardio supports earlier diagnosis, shortens both diagnosis and treatment timelines, improves clinical efficiency, provides real-time support for clinical decision-making, and helps care teams manage cardiac patients more effectively.
“We are pleased to welcome AISAP to the MedAxiom community. Point-of-care ultrasound has the potential to provide clinicians with important information closer to the patient, and AISAP is applying AI to make those insights available quickly and efficiently,” said Joe Sasson, PhD, MedAxiom’s executive vice president of Ventures and chief commercial officer. “AISAP’s knowledge and experience in cardiac AI and point-of-care ultrasound will provide valuable insight to the MedAxiom community as cardiovascular programs explore new approaches to identifying disease, improving workflows, and delivering timely care.”
“This partnership brings our mission into a single, shared action: diagnosing as many patients as possible, as soon as possible,” said Eran Taus, CEO of AISAP. “By integrating our AI platform into MedAxiom’s network of cardiovascular programs, we are helping extend high-quality cardiac diagnostics to every point of care, including underserved and rural communities where specialist access is often limited.”
About MedAxiom
MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s premier source for organizational performance solutions. MedAxiom is transforming cardiovascular care by combining the knowledge and power of hundreds of cardiovascular organization members, thousands of administrators, clinicians and revenue cycle experts, and dozens of industry partners. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.
About AISAP
AISAP is a health-technology company bringing AI-powered cardiac diagnostics to the point of care, helping cardiovascular programs diagnose disease earlier, streamline workflows, and extend specialist-level insight to every care setting. Its flagship platform, AISAP Cardio, is an FDA-cleared AI solution that turns bedside cardiac ultrasound scans into comprehensive cardiac assessment reports, reading 12 key measurements and findings from ejection fraction to valvular pathology to support physician diagnosis, with reports integrating automatically into any EHR system.
AISAP’s clinical validation was conducted in partnership with leading U.S. academic medical centers, including Massachusetts General Hospital, Mayo Clinic, Inova Health and Thomas Jefferson University Hospital.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
